Back to User profile » Dr Junyi Wu
Papers published by Dr Junyi Wu:
Prognostic Value of the SEA Score in Double-Negative DCP/AFP Unresectable HCC with Triple Therapy
Lin H, Ran F, Wu J, Huang C, Wu J, Liu C, Wang X, Ya H, Jiang K, Gu J, Yan M, Li S
Journal of Hepatocellular Carcinoma 2026, 13:606282
Published Date: 16 June 2026
Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors
Wei SM, Zeng ZX, Pan RJ, Wu JY, Wu JY, Luo MC, Li YN, Li H, Liu DY, Ou XY, Zhang ZB, Zhou JY, Li B, Zhuang SW, Yan ML
Journal of Inflammation Research 2025, 18:7545-7557
Published Date: 10 June 2025
Combination Therapy of Transarterial Chemoembolization, Lenvatinib, and PD-1 Inhibitors Achieves Significant Tumor Response in Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report
Fu Y, Wu J, Wu J, Li Y, Zeng Z, Liu D, Li H, Ou X, Lin Z, Wei S, Song H, Yan M
Cancer Management and Research 2025, 17:793-799
Published Date: 13 April 2025
Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study
Liu DY, Li YN, Wu JY, Zeng ZX, Fu YK, Li H, Ou XY, Zhang ZB, Wang SJ, Wu JY, Yan ML
Journal of Hepatocellular Carcinoma 2024, 11:2339-2349
Published Date: 25 November 2024
Impact of Duration of Adjuvant Therapy on Patients with Initially Unresectable Hepatocellular Carcinoma After Conversion Surgery: A Propensity Score Matching Study
Lin ZT, Wei SM, Wu JY, Zhang ZB, Wang SJ, Zhou JY, Luo MC, Zeng ZX, Ou XY, Fu YK, Li H, Liu DY, Wu JY, Yan ML
Journal of Hepatocellular Carcinoma 2024, 11:1777-1787
Published Date: 24 September 2024
Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?
Wu JY, Wu JY, Liu DY, Li H, Zhuang SW, Li B, Zhou JY, Huang JY, Zhang ZB, Li SQ, Yan ML, Wang YD
Journal of Hepatocellular Carcinoma 2023, 10:2161-2171
Published Date: 5 December 2023
Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy
Luo MC, Wu JY, Wu JY, Lin ZT, Li YN, Zeng ZX, Wei SM, Yan ML
Journal of Hepatocellular Carcinoma 2023, 10:1827-1837
Published Date: 12 October 2023
Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
Li SQ, Wu JY, Wu JY, Xie H, Li JH, Zeng ZX, Fu YK, Liu DY, Li H, Chen WZ, Huang JY, Yan ML
Journal of Hepatocellular Carcinoma 2023, 10:1799-1811
Published Date: 11 October 2023
Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy
Wu JY, Wang ZX, Zhang G, Lu X, Qiang GH, Hu W, Ji AL, Wu JH, Jiang CP
International Journal of Nanomedicine 2018, 13:1265-1280
Published Date: 5 March 2018